Federated Hermes’s Immunocore IMCR Stock Holding History

Federated Hermes’s Portfolio IMCR Stock Details IMCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-74,361	Closed	-$3.68M	–	2163
2023 Q1	$3.68M	Buy	+74,361	New	+$4.18M	0.01%	780

Other funds holding IMCR

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return

PAMS

Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Federated Hermes's IMCR Position: Q2 2023 in Review

Federated Hermes sold out of Immunocore (IMCR) in Q2 2023, closing a stake of 74,361 shares — an estimated $3.68M sold.

Federated Hermes first reported a position in IMCR in Q1 2023 and held it in 1 quarter. The position peaked at $3.68M in Q1 2023. 120 funds tracked by Wall St. Rank hold IMCR as of Q2 2023.

Federated Hermes reported no remaining Immunocore position as of Q2 2023 after selling out during the quarter.
Federated Hermes sold 74,361 Immunocore shares in Q2 2023, an estimated $3.68M.
Federated Hermes first reported a position in Immunocore in Q1 2023 and held it in 1 quarter.
Federated Hermes's Immunocore position peaked at $3.68M in Q1 2023.
120 funds tracked by Wall St. Rank held Immunocore as of Q2 2023.

Based on Federated Hermes's 13F filing for Q2 2023, filed 14 Aug 2023.